Novartis and Amgen launch new Alzheimer's study
Novartis and Amgen are expanding their collaboration with the Banner Alzheimer’s Institute, launching a new study to assess whether their drug will slow the progression of Alzheimer’s disease.
The study will look at Novartis’ $NVS BACE1 inhibitor therapy called CNP520 (jointly developed with Amgen $AMGN), to see if it can prevent or delay the onset of Alzheimer’s in a high-risk population.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
